|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 9/10 | |
| C12N 15/54 | |||
| C07K 16/00 |
| (11) | Number of the document | 2264151 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10075271.6 |
| Date of filing the European patent application | 2004-01-22 | |
| (97) | Date of publication of the European application | 2010-12-22 |
| (45) | Date of publication and mention of the grant of the patent | 2016-04-20 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 441307 P | 2003-01-22 | US | |
| 491254 P | 2003-07-31 | US | |
| 495142 P | 2003-08-15 | US |
| (72) |
Umana, Pablo, CH
Bruenker, Peter, CH
Ferrara Koller, Claudia, CH
Suter, Tobias, CH
|
| (73) |
Roche Glycart AG,
Wagistrasse 18, 8952 Schlieren-Zuerich,
CH
|
| (54) | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |